Plasma tissue kallikrein level is negatively associated with incident and recurrent stroke: A multicenter case-control study in China

Annals of Neurology

Volumn 70, Issue 2, 2011, Pages 265-273

  Zhang, Qin ^a   Ding, Hu ^a   Yan, Jiangtao ^a   Wang, Wei ^a   Ma, Aiqun ^b   Zhu, Zhiming ^c   Cianflone, Katherine ^d   Hu, Frank B ^e   Hui, Rutai ^f   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Systems Engineering Institute   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITÉ LAVAL   (Canada)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TISSUE KALLIKREIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CASE CONTROL STUDY; CHINESE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANIMALS; CASE-CONTROL STUDIES; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; STROKE; TISSUE KALLIKREINS;

EID: 80051478155     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22404     Document Type: Article

References (38)

1. Bazzano LA, Gu D, Reynolds K, et al. Alcohol consumption and risk for stroke among Chinese men. Ann Neurol 2007; 62: 569-578.
2. Reed DM,. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol 1990; 131: 579-588. (Pubitemid 20137226)
3. Wong TY, Klein R, Couper DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358: 1134-1140. (Pubitemid 32971846)
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158. (Pubitemid 36398384)
5. Samdani AF, Dawson TM, Dawson VL,. Nitric oxide synthase in models of focal ischemia. Stroke 1997; 28: 1283-1288. (Pubitemid 27248908)
6. Chao J, Bledsoe G, Yin H, Chao L,. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem 2006; 387: 665-675. (Pubitemid 43964788)
7. Groger M, Lebesgue D, Pruneau D, et al. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2005; 25: 978-989. (Pubitemid 41061713)
8. Hobbs A, Foster P, Prescott C, et al. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 2004; 110: 1231-1235. (Pubitemid 39202338)
9. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005; 99: 6-38. (Pubitemid 41366887)
10. Hecquet C, Tan F, Marcic BM, Erdos EG,. Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 2000; 58: 828-836.
11. Regoli D, Rhaleb NE, Drapeau G, Dion S,. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990; 15 (suppl 6): S30-S38.
12. Chao J, Chao L,. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 2005; 90: 291-298. (Pubitemid 40685841)
13. Zhao C, Wang P, Xiao X, et al. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension 2003; 42: 1026-1033. (Pubitemid 37413748)
14. Ling L, Hou Q, Xing S, et al. Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats. Brain Res 2008; 1206: 89-97.
15. Yuan G, Deng J, Wang T, et al. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5′-monophosphate-activated protein kinase signaling pathways. Endocrinology 2007; 148: 2016-2026. (Pubitemid 46997049)
16. Zhang JJ, Chao L, Chao J,. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke 1999; 30: 1925-1931; discussion 1931-1932.
17. Xia CF, Yin H, Borlongan CV, et al. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 2004; 43: 452-459. (Pubitemid 38174153)
18. Xia CF, Yin H, Yao YY, et al. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther 2006; 17: 206-219. (Pubitemid 43262036)
19. Lawton WJ, Fitz AE,. Urinary kallikrein in normal renin essential hypertension. Circulation 1977; 56: 856-859. (Pubitemid 8235195)
20. Zinner SH, Margolius HS, Rosner B, Kass EH,. Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation 1978; 58: 908-915. (Pubitemid 9042776)
21. Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-1621. (Pubitemid 43739421)
22. Slee VN,. The International Classification of Diseases: ninth revision (ICD-9). Ann Intern Med 1978; 88: 424-426.
23. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
24. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
25. Brash AR,. Arachidonic acid as a bioactive molecule. J Clin Invest 2001; 107: 1339-1345. (Pubitemid 32522025)
26. Berry TD, Hasstedt SJ, Hunt SC, et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989; 13: 3-8. (Pubitemid 19047274)
27. Koch M, Spillmann F, Dendorfer A, et al. Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. Eur J Pharmacol 2006; 550: 143-148. (Pubitemid 44574499)
28. Pons S, Griol-Charhbili V, Heymes C, et al. Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. Eur J Heart Fail 2008; 10: 343-351.
29. Chao J, Yin H, Gao L, et al. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension 2008; 52: 715-720.
30. Wang T, Hou LB, Liu ZJ, et al. Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats. Acta Pharmacol Sin 2007; 28: 1898-1906. (Pubitemid 350198344)
31. Murakami H, Yayama K, Miao RQ, et al. Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 1999; 34: 164-170. (Pubitemid 29409209)
32. Emanueli C, Salis MB, Chao J, et al. Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. Arterioscler Thromb Vasc Biol 2000; 20: 1459-1466. (Pubitemid 30353874)
33. Tu L, Xu X, Wan H, et al. Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther 2008; 19: 318-330. (Pubitemid 351591428)
34. Wang T, Li H, Zhao C, et al. Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 2004; 11: 1342-1350. (Pubitemid 39213999)
35. Liu L, Zhang R, Liu K, et al. Tissue kallikrein protects cortical neurons against in vitro ischemia-acidosis/reperfusion-induced injury through the ERK1/2 pathway. Exp Neurol 2009; 219: 453-465.
36. Liu L, Zhang R, Liu K, et al. Tissue kallikrein alleviates glutamate-induced neurotoxicity by activating ERK1. J Neurosci Res 2009; 87: 3576-3590.
37. Vandell AG, Larson N, Laxmikanthan G, et al. Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J Neurochem 2008; 107: 855-870.
38. Campbell DJ, Kladis A, Zhang Y, et al. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 2010; 53: 779-785.